Ordesekimab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Ordesekimab Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 16 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: CONDITIONAL GO
Decision memo
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
The central underwriting question is whether Ordesekimab can convert its Monoclonal antibody profile and IL-15 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Ordesekimab (query alias: Ordesekimab) |
|---|---|
| Modality / target | Monoclonal antibody; IL-15; IL-15 inhibitors |
| Highest global status | Phase 2 |
| Originator | Genmab A/S |
| Active developers | Amgen, Inc. |
The MCP disease footprint includes Vitiligo. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT04424927 | Phase 2 | Completed | 388 | Primary endpoint not disclosed in English source |
| NCT04338581 | Phase 2 | Completed | 60 | Primary endpoint not disclosed in English source |
| NCT03439475 | Not Applicable | No longer available | Not disclosed | Primary endpoint not disclosed in English source |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Evaluation of AMG 714 for Vitiligo: A Phase 2a Randomized Double Blind Placebo Controlled Trial (ITN086AI)
Phase 2; n=60; evaluation: Not stated in English source. Reported fields: Proportion of Participants Achieving a ≥ 35% Improvement From Baseline in the Facial Vitiligo Area Scoring Index (F-VASI35) at Week 24 = 0.150 % (95%CI, 0.057 - 0.298); Proportion of Participants Achieving a ≥ 35% Improvement From Baseline in the Facial Vitiligo Area Scoring Index (F-VASI35) at Week 24 = 0.053 % (95%CI, 0.001 - 0.260)
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of PRV-015 in Adult Patients With Non-Responsive Celiac Disease as an Adjunct to a Gluten-free Diet
Phase 2; n=388; evaluation: Not stated in English source. Reported fields: Absolute Change From Baseline in Celiac Disease Patient-Reported Outcome Abdominal Symptoms Domain Score Through Week 24(LS Mean) = -1.32 Point (95%CI, -1.66 to -0.98)
AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS
Phase 2; n=not disclosed; evaluation: Negative. Reported fields: primary endpoint = did not meet primary or secondary endpoints. Not Met; primary endpoint = did not meet primary or secondary endpoints. Not Met
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Ordesekimab addresses Vitiligo. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The MCP screen returned 2 matched transaction record(s) under the scope “asset-specific.” Partner activity is a market-validation signal, but it does not establish net present value.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2018-11-05 | Amgen And Provention Bio Announce Co-Development Collaboration In Celiac Disease | Phase 2 | US$150.0M milestones |
| 2001-01-01 | Genmab entered into a new agreement with Immunex Corporation for the exclusive worldwide rights to Immunex’s patent estate relating to antibodies towards IL15 and IL15r | Preclinical | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Antibody formulations”. The milestone feed surfaced a patent-application signal described as “Antibody formulations”. The milestone feed surfaced a patent-application signal described as “Antibody therapy”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.
7. Principal risks and diligence gates
- Clinical differentiation versus current standards and pipeline competitors
- Safety, dose optimization, and long-term tolerability
- Patent scope, territorial rights, manufacturing, and commercial positioning
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
CONDITIONAL GO
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 2026-09-16. Counts and status fields may change as source records update.
